| Literature DB >> 35186674 |
Ankit Kumar Dubey1,2, Suman Kumar Chaudhry3, Harikesh Bahadur Singh4, Vijai Kumar Gupta5,6, Ajeet Kaushik7.
Abstract
Optimized therapeutic bio-compounds supported by bio-acceptable nanosystems (i.e., precise nanomedicine) have ability to promote health via maintaining body structure, organ function, and controlling chronic and acute effects. Therefore, nano-nutraceuticals (designed to neutralize virus, inhibit virus bindings with receptors, and support immunity) utilization can manage COVID-19 pre/post-infection effects. To explore these approaches well, our mini-review explores optimized bio-active compounds, their ability to influence SARS-CoV-2 infection, improvement in performance supported by precise nanomedicine approach, and challenges along with prospects. Such optimized pharmacologically relevant therapeutic cargo not only affect SARS-CoV-2 but will support other organs which show functional alternation due to SARS-CoV-2 for example, neurological functions. Hence, coupling the nutraceuticals with the nano-pharmacology perspective of higher efficacy via targeted delivery action can pave a novel way for health experts to plan future research needed to manage post COVID-19 infection effect where a longer efficacy with no side-effects is a key requirement.Entities:
Keywords: COVID-19 infection; Immunity; Nanoparticles; Nutraceuticals; Phytochemicals; SARS-CoV-2; Therapeutics
Year: 2022 PMID: 35186674 PMCID: PMC8832856 DOI: 10.1016/j.btre.2022.e00712
Source DB: PubMed Journal: Biotechnol Rep (Amst) ISSN: 2215-017X
Fig. 1Natural products and respective phytochemical constituents for COVID-19 prevention and treatment.
Fig. 2Domain representation of SARS-CoV-2 nsp13 and the structural ribbon representation of the SARS-CoV-2 helicase with potential inhibitors.
Fig. 3Overview of the SARS-CoV2 nsp3 structural and genomic organization along with possible inhibitors of SARS-CoV-2 papain-like protease (PLpro).
Fig. 4Structural representation of SARS-CoV-2 Mpro monomer nsp5 composed of: N-terminal domain I (blue), domain II (golden yellow), and C-terminal domain III (light blue) along with possible phytochemical inhibitors. Substrate recognition site in (green and red) and catalytic dyad residues, His41 and Cys145 are highlighted and labeled.
List of dietary supplements in clinical trials of COVID-19 (Source: clinicaltrials.gov).
| Food supplements | Identifier | Study |
|---|---|---|
| Honey | Efficacy of Natural Honey Treatment in Patients with Novel Coronavirus | |
| Starch | The Role of Resistant Starch in COVID-19 Infection | |
| Methylene Blue | Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19) | |
| Vitamin A | Vitamin A Supplementation in Children with Moderate to Severe COVID-19 | |
| Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19 (Micro Cov Aging) | ||
| Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction | ||
| Vitamin B | Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19 | |
| Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women | ||
| Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19 (COVit-2) | ||
| Vitamin C | Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia | |
| Use of Ascorbic Acid in Patients with COVID 19 | ||
| Safety Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) | ||
| Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation (AVoCaDO) | ||
| Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) | ||
| Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment | ||
| The effect of melatonin and Vitamin C on COVID-19 | ||
| Efficacy and safety of high-dose vitamin C combined with Chinese medicine against coronavirus pneumonia (COVID-19) | ||
| The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: A Multicenter Randomized Controlled Trial | ||
| High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients with Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial. (HDIVC) | ||
| Vitamin D | Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19 | |
| COvid-19 and Vitamin D Supplementation: A Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection | ||
| Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 (ZnD3-CoVici) | ||
| N-terminal Pro-B-type natriuretic peptide and vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia | ||
| Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic | ||
| A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons with Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members | ||
| Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial | ||
| Low vs. moderate to high-dose vitamin D for prevention of COVID-19 | ||
| Vitamin D3 Levels in COVID-19 Outpatients from Western Mexico: Clinical Correlation and Effect of Its Supplementation | ||
| Vitamin E | Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients with and Without Septic Shock Secondary to COVID-19 Severe Pneumonia | |
| Vitamin K | A Phase 2, double blind, randomized, placebo-controlled clinical trial to investigate the safety and effects of oral vitamin K2 supplementation in COVID-19 | |
| Dietary Supplements to Reduce Symptom Severity and Duration in People With SARS-CoV-2: A Randomized, Double Blind, Placebo Controlled Clinical Trial | ||
| Zinc | Sub-cutaneous Ivermectin in Combination with and Without Oral Zinc: A Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients | |
| Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19? | ||
| Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial) | ||
| Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study | ||
| Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study | ||
| A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection | ||
| Copper | Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19 | |
| Mouth-to-mouth Ventilation Efficiency Through Breathable Self-Sterilizing Respirator During BLS in COVID-19 Pandemic: A crossover Simulation-based Study | ||
| Efficacy of Micronutrient Dietary Supplementation in Reducing Hospital Admissions for COVID-19: A Double-blind, Placebo-controlled, Randomized Clinical Trial | ||
| Selenium | Selenium as a Potential Treatment for Moderately ill, Severely ill, and Critically ill COVID-19 Patients | |
| Effect of a Nutritional Support System to Reduce Complications in Patients with Covid-19 and Comorbidities in Stage III | ||
| Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial | ||
| Chronic Fatigue Etiology and Recovery in Covid-19 Patients: The Role of Fatigability and Stay in Intensive Care | ||
| Calcium | Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients with Covid-19 Pneumonia: A Single Center Experience in Turkey | |
| The Coronavirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Investigation (CORONACION) Randomized Clinical Trial | ||
| Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients with Mild Coronavirus-19 (COVID-19) Disease. |
Fig. 5Nano-approach for the targeted delivery of phytoconstituents in the body.